Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Paclitaxel + Trastuzumab + Pertuzumab as Pre-Op for Inflammatory BrCa

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2016 by Dana-Farber Cancer Institute
Sponsor:
Information provided by (Responsible Party):
Beth Overmoyer, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01796197
First received: February 20, 2013
Last updated: May 25, 2016
Last verified: May 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: March 2020
  Estimated Primary Completion Date: March 2017 (Final data collection date for primary outcome measure)